GBGajjala Venkata Ramesh Babu

Gajjala Venkata Ramesh Babu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gajjala Venkata Ramesh Babu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cloud computing environment based hierarchical anomaly intrusion detection system using artificial neural network

    by Mangalapalli Vamsikrishna, Garapati Swarna Latha, Gajjala Venkata Ramesh Babu, Koppisetti Giridhar, Lakshmeelavanya Alluri, Giddaluru Somasekhar, Bhimunipadu Jestadi Job Karuna Sagar, Naresh Dondapati

    Nowadays, computer technology is essential to everyday life, including banking, education, entertainment, and communication. Network security is essential in the digital era, and detecting intrusion threats is the most difficult problem. As a result, the network is monitored for unusual activity using this hierarchical anomaly intrusion detection system, and when these actions are detected, an alert is generated. This hierarchical anomaly intrusion detection system, which uses artificial neural network (ANN) and is implemented on a cloud computing environment, analyzes data even in the high levels of traffic and protects computer networks and data from malicious activity. As a result, this system shows better detection, accuracy, and precision rates.


  • Open Access

    AI AND DEEP LEARNING IN DRUG DISCOVERY: ADVANCES, BENCHMARKS, AND FUTURE CHALLENGES

    by L. Sowjanya Upadhyayula, Mallu Mallikarjuna, Madduri Padmavathamma, Gv Ramesh Babu

    Artificial intelligence (AI) and deep learning (DL) are redefining the landscape of modern drug discovery by transforming data-driven prediction, molecular design, and optimization workflows. DL architectures such as convolutional, recurrent, graph-based, and transformer models enable the efficient integration of chemical, biological, and clinical datasets to predict binding interactions, structural conformations, and pharmacokinetic behavior with remarkable accuracy. The incorporation of AlphaFold-like structural predictors, generative adversarial networks (GANs), and reinforcement learning frameworks has accelerated target identification, virtual screening, and de novo compound generation. These developments have significantly reduced the cost and time associated with early-stage drug development while improving hit quality and safety evaluation. However, challenges persist, including limited interpretability, dataset bias, and computational complexity. The review highlights emerging strategies such as explainable AI, multimodal learning, and digital twin modelling to overcome these limitations. Collectively, DL-driven approaches mark a pivotal transition toward predictive, transparent, and sustainable pharmaceutical innovation that bridges computational and experimental discovery.